Progress will hold a conference call to review its financial results for the fiscal third quarter of 2023 at5:00 p.m. ETonTuesday, September 26, 2023. Participants must register for the conference call here:https://register.vevent.com/register/BI72285db48dff4b828a4154f9ed1f81a...
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial result for the year end 2023 and highlighted recent Company progress.
The results of this first analysis confirm a thesis already present in the literature, according to which a substantial amount of variation can be attributed to different rates in the growth of knowledge across medical schools.Grassia, Maria Gabriella...
The aim of this study was to analyse and compare the annual C-EHRN HCV monitoring results for the period 2020 to 2023 and examine the progress made over the past four years in the availability of interventions as part of the HCV continuum-of-care for PWID across European countries. ...
when we reported our Q4 results. Let me address that last point for a moment. On March 14th, we issued an 8-K indicating that we have no material exposure to Silicon Valley Bank or Signature Bank. While we do not like to witnessed this kind of instability, our primary concern is for ...
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results. Phase 1/2 study of KB-0742 is on track to clear 80mg ...
Four roundtable discussions between industry experts and policymakers, with the results published in the report "Bridging the Gap Between Technology and Regulation with Dialogue." A roundtable on the future of DeFi held with EUBOF and the European Blockchain Association (recording available here). ...
1,822 SBA 7(a) loans made in FY 2023. Deployed $42.8 million in capital to Small Business Investment Companies (SBICs). Dedicated 249,382 hours to volunteering in our communities. Contributed $53.6 million through the bank and the M&T Charitable Foundation to 4,250 nonprofit organizations....
“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors. We showed that both RMC-6236 and RMC-6291 as single agents can deliver clinically meaningful antitumor responses at doses that are generally safe and well tolera...
Omega Therapeutics today announced financial results for the first quarter ended March 31, 2023, and highlighted recent Company progress.